Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma

26 Jun 2020

Abstract excerpt

BACKGROUND: PD-L1 (programmed cell death 1 ligand 1) expression in melanoma has been associated with a better response to anti-PD-1 (programmed cell death 1) therapy. However, patients with PD-L1-negative melanomas can respond to anti-PD-1 blockade, suggesting that the other PD-1 ligand, PD-L2 (programmed cell death 1 ligand 2), might also be relevant for efficacy of PD-1 inhibition. We investigated PD-L2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cutaneous Melanoma Detection and Management
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32586358
DOI: 10.1186/s13148-020-00883-9

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanomaPMID 32586358Read ↗

PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survivalSemantic proximity Read ↗

CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patientsSemantic proximity Read ↗

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.Semantic proximity Read ↗

Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapySemantic proximity Read ↗

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.Semantic proximity Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

CD274 Alterations and PD-L1 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Patients With Melanoma: Relationships to Histopathologic Features and Outcomes.Semantic proximity Read ↗

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.Semantic proximity Read ↗

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to ImmunotherapySemantic proximity Read ↗

Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial RelationshipSemantic proximity Read ↗

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.